Rensen PC - Search Results

1

Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.

Li Z, Wang Y, van der Sluis RJ, van der Hoorn JW, Princen HM, Van Eck M, Van Berkel TJ, Rensen PC, Hoekstra M. Li Z, et al. Among authors: rensen pc. Biochem Pharmacol. 2012 Sep 15;84(6):821-9. doi: 10.1016/j.bcp.2012.06.020. Epub 2012 Jun 27. Biochem Pharmacol. 2012. PMID: 22750059

2

Selective liver targeting of antivirals by recombinant chylomicrons--a new therapeutic approach to hepatitis B.

Rensen PC, van Dijk MC, Havenaar EC, Bijsterbosch MK, Kruijt JK, van Berkel TJ. Rensen PC, et al. Nat Med. 1995 Mar;1(3):221-5. doi: 10.1038/nm0395-221. Nat Med. 1995. PMID: 7585037

3

Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo.

Rensen PC, van Berkel TJ. Rensen PC, et al. J Biol Chem. 1996 Jun 21;271(25):14791-9. doi: 10.1074/jbc.271.25.14791. J Biol Chem. 1996. PMID: 8662966 Free article.

4

Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Rensen PC, de Vrueh RL, van Berkel TJ. Rensen PC, et al. Clin Pharmacokinet. 1996 Aug;31(2):131-55. doi: 10.2165/00003088-199631020-00005. Clin Pharmacokinet. 1996. PMID: 8853935 Review.

5

Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo.

Rensen PC, Herijgers N, Netscher MH, Meskers SC, van Eck M, van Berkel TJ. Rensen PC, et al. J Lipid Res. 1997 Jun;38(6):1070-84. J Lipid Res. 1997. PMID: 9215536 Free article.

6

Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents.

Rensen PC, Schiffelers RM, Versluis AJ, Bijsterbosch MK, Van Kuijk-Meuwissen ME, Van Berkel TJ. Rensen PC, et al. Mol Pharmacol. 1997 Sep;52(3):445-55. doi: 10.1124/mol.52.3.445. Mol Pharmacol. 1997. PMID: 9281607

7

Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.

Versluis AJ, Rump ET, Rensen PC, Van Berkel TJ, Bijsterbosch MK. Versluis AJ, et al. Among authors: rensen pc. Pharm Res. 1998 Apr;15(4):531-7. doi: 10.1023/a:1011917508056. Pharm Res. 1998. PMID: 9587947

8

Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.

Versluis AJ, Rensen PC, Rump ET, Van Berkel TJ, Bijsterbosch MK. Versluis AJ, et al. Among authors: rensen pc. Br J Cancer. 1998 Dec;78(12):1607-14. doi: 10.1038/bjc.1998.730. Br J Cancer. 1998. PMID: 9862571 Free PMC article.

9

Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor.

Sliedregt LA, Rensen PC, Rump ET, van Santbrink PJ, Bijsterbosch MK, Valentijn AR, van der Marel GA, van Boom JH, van Berkel TJ, Biessen EA. Sliedregt LA, et al. Among authors: rensen pc. J Med Chem. 1999 Feb 25;42(4):609-18. doi: 10.1021/jm981078h. J Med Chem. 1999. PMID: 10052968

10

Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.

Versluis AJ, Rump ET, Rensen PC, van Berkel TJ, Bijsterbosch MK. Versluis AJ, et al. Among authors: rensen pc. J Pharmacol Exp Ther. 1999 Apr;289(1):1-7. J Pharmacol Exp Ther. 1999. PMID: 10086980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters